

## Calcitonin Gene-Related Peptide (CGRP) Antagonist Drug Use Criteria

Created: October 2018

Reviewed: August 2020, August 2021

Includes:

### Preventative Migraine Therapy

<b>Aimovig®</b>	<i>Erenmab-aooe</i>
<b>Ajovy®</b>	<i>Fremanezumab-vfrm</i>
<b>Emgality®</b>	<i>Galcanezumab-gnlm</i> (migraine and cluster headache preventatives)
<b>Vyepti®</b>	<i>Eptinezumab jjmr</i>
<b>Nurtec®</b>	<i>Rimegepant</i>

### Acute Migraine Therapy

<b>Nurtec®</b>	<i>Rimegepant</i>
<b>Ubrelvy®</b>	<i>Ubrogepant</i>

### Guideline for Use:

For consideration of coverage refer to the Oregon Medicaid Fee-For-Service Drug Use Criteria at:

[https://www.orpdl.org/durm/PA\\_Docs/CGRPInhibitors.pdf](https://www.orpdl.org/durm/PA_Docs/CGRPInhibitors.pdf)

### **Rationale:**

To ensure medically appropriate, cost-effective use of medication based on the best available evidence.

### **References:**

1) Oregon Medicaid FFS Drug Use Criteria. Calcitonin Gene-Related Peptide (CGRP) Antagonists. Drug Use Research and Management. Health Systems Division. Oregon Health Authority.